Mark Emberton, MD, FRCS Urol, from University College London Hospitals NHS Foundation Trust, London, UK discusses the value of MRI in prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. Prof. Emberton explains that MRI allows the cancer to be identified, described, characterized and biopsied better, and will hopefully in future allow it to be treated better. He describes the PROMIS study (NCT01292291), and highlights that at EAU 2017, the ramifications of these data are just being explored. He concludes that MRI in prostate cancer offers more opportunity, fewer and better biopsies, better risk stratification, and he is hopeful that these will translate to better therapeutic allocation.
Просмотров: 375 VJOncology
Our panel of experts share their ESMO 2017 highlights and offer their opinion on current, and future standard-of-care within prostate cancer treatment. Some of the panels key highlights include additional STAMPEDE data which share further efficacy results; this time assessing the addition of abiraterone acetate plus prednisolone vs. docetaxel for patients with high risk prostate cancer starting long-term androgen deprivation therapy; and additional data from STAMPEDE looking at the outcomes in non-metastatic (M0) patients. Further data from LATITUDE, looked at patient reported outcomes (PRO) and the interpretation of the data from FACT-P and EQ-5D-5L questionnaires, with some key significant parameters being delayed time to pain and fatigue intensity and interference progression shown in the ADT AA P arm. Phase 3 results were discussed, assessing whether docextaxel with androgen suppression for high-risk localised prostate cancer for patients with relapsing PSA after radical prostatectomy and/or radiotherapy - the trial was designed to compare AS (triptorelin, every 3 months for 1 year) versus AS D in patients with ≥ 3 rising PSA values. Our panel also discussed the ARASENS trial, which is evaluating darolutamide plus standard ADT þ docetaxel in men with mHSPC, and the TRITON clinical trial programme, evaluating the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). This trial raised further discussion on the need for guidelines to signpost what patients will require BRCA germline and somatic testing in the future. This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
Просмотров: 667 ecancer
Dr. Thomas E. Keane presented “Vitamin D and Prostate Cancer” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016. STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME). The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal. Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
Просмотров: 2118 Grand Rounds in Urology
Update on the survival results from the STAMPEDE trial (NCT00268476), investigating radiotherapy to the primary tumour for men with newly-diagnosed metastatic prostate cancer. Presented by Chris Parker, BM, BChir, MD, FRCR, MRCP from the Royal Marsden NHS Foundation Trust, London, UK, at the prostate cancer press briefing at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Results showed that by treating the primary tumour with radiotherapy, there was a significant survival benefit in men with low metastatic burden.
Просмотров: 129 VJOncology
Christopher J. Logothetis ESO Observatory, held during the "Advanced Prostate Cancer Conference (APCC)" on 10 March 2017 in St. Gallen, Switzerland.
Просмотров: 116 TheESOChannel
International Conference on Prostate Cancer provides opportunities to exchange novel ideas and share experiences. The conference throws light on thought provoking topics and recent research in the field of Prostate Cancer like Future Perspectives on Prostate Cancer, Benign Prostatic Hyperplasia Treatments for Castration Resistant Prostate Cancer, Translational Research and Pathology Screening and early diagnosis of prostate cancer, Prostatitis, Radical Prostatectomy, Clinical Trials on Prostate Cancer, Prostate Cancer Side Effects and Management, State-of-the art: vision on the future, and many more.It is an immense pleasure and privilege having you here with us to honor your hard-earned scientific discoveries, innovations and would like you to share, extend and impart your valuable thoughts to the global scientific community.Through the theme“Advancement in Prostate Cancer Research and Treatment”conference will explore the advances in the study of Prostate Cancer Research by connecting scientists within and across disciplines at sessions held at the venue. Prostate Cancer-2015 has been designed in an interdisciplinary manner and provides you unique opportunity to meet up with peers from both industry and academia and establish a scientific network between them.During Prostate Cancer-2015 conference you will be able to exchange ideas and experiences across a variety of topics that cover the latest insights in important aspects of Prostate Cancer Research.
Просмотров: 31 OMICS International
Dr. Noel W. Clarke presented “Combination Therapy in Hormone-Sensitive Prostate Cancer” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016. STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME). The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal. Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
Просмотров: 232 Grand Rounds in Urology
J. Bellmunt reviews the main findings presented at EMUC 2014. Hormone + RT confirmed as standard of care for localised prostate cancer; potential for newer surgery approach in larger non-muscle invasive bladder tumours; new data showing that AR activity is involved in DNA repair. http://www.esmo.org Video produced by the European Society for Medical Oncology (ESMO)
Просмотров: 276 European Society for Medical Oncology
Report from day 3 of the ESMO 2010 Congress in Milan. This video includes top late breaking abstracts: focus on metastatic castration resistant prostate cancer, ovarian cancer and pancreatic tumors and a summary of the congress by David Kerr, ESMO President. Video produced by the European Society for Medical Oncology (ESMO)
Просмотров: 635 European Society for Medical Oncology
B. Tombal digs into AR signalling importance in prostate and in prostate cancer. Removing testosterone has been the base of the treatment of prostate cancer for 60 years. However, the researchers realised in last few years that besides AR-dependent pathway, there are AR-independent pathways that probably make the cells resistant to treatment. But in a vast majority of patients, the AR is one of the main drivers of the prostate cancer. He discusses the generations of therapeutics targeting the AR in prostate cancer. http://www.esmo.org Video produced by the European Society for Medical Oncology (ESMO)
Просмотров: 389 European Society for Medical Oncology
Silke Gillessen, Genitourinary tumours, prostate track Chair, reveals which sessions of the track are absolutely unmissable! Produced by the European Society for Medical Oncology http://www.esmo.org
Просмотров: 75 European Society for Medical Oncology
Christian Stief, MD, from Ludwig-Maximilians-University, Munich, Germany discusses developments in prostate cancer presented at a video session at the European Association of Urology (EAU) conference 2017 in London, UK. He explains that prostate fusion biopsy, which combines MRI and ultrasound imaging, is becoming more readily available, and comparable to biopsy carried out in the MRI apparatus. Prof. Stief points out that fusion biopsy is cost effective and much easier for patients to endure, while also giving precise information on the tumor itself and the extent of the tumor. He also speaks about cryotherapy, where a specific spot undergoes cryotherapy right after biopsy as an early therapy in an early stage of prostate cancer.
Просмотров: 77 VJOncology
Martin Spahn, MD, from the University Hospital Bern, Bern, Switzerland, discusses the challenges of imaging modalities in oligometastatic prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. Currently, especially with PSMA PET CT scans, the problem is standardisation of compounds. Every institution prepares and uses different compounds, which in turn affects how they are compared. He explains that the end result of standardising these modalities will be using the most effective treatment, and therefore improving patient outcomes.
Просмотров: 31 VJOncology
Interview with Prof. F. Hamdy (UK) on the ProtecT trial, a UK research project on Prostate Testing for Cancer and Treatment for EAU17.
Просмотров: 512 European Association of Urology
American Academy of Arts & Sciences 1983rd Stated Meeting Francis Amory Prize Ceremony and Symposium March 14, 2012 House of the Academy Cambridge, MA
Просмотров: 2313 American Academy of Arts & Sciences
Drs. Deepak A. Kapoor, Serge Ginzburg, and Peter M. Knapp explain the serious flaws in the Prostate, Lung, Colorectal and Ovarian Screening Trial (PLCO) during the Q & A session of the Congressional Briefing. Prostate, Lung, Colorectal and Ovarian Screening Trial (PLCO) European Randomized study of Screening for Prostate Cancer (ERSPC) Congressional Briefing In collaboration with the Congressional Men’s Health Caucus and Prostate Cancer Task Force - Congressmen Markwayne Mullin (OK) and Donald Payne, Jr. (NJ) (Co-Chairs) 1. Opening Remarks Ana N. Fadich – Introduction, VP, Men’s Health Network Congresswoman Marsha Blackburn, 7th District, Tennessee 2. Speakers Deepak A. Kapoor, MD, Chairman and CEO, Integrated Medical Professionals Serge Ginzburg, MD, FACS, Director, Einstein Prostate Cancer Center, Department of Urology, Albert Einstein Medical Center Peter M. Knapp, MD, Co-Founder and Director, Strand Diagnostics Darrell Sabbs, Community Benefit Manager/Legislative Affairs, Phoebe Putney Health System 3. Comments Bernard Wooden, Patient Advocate, Men's Health Network Tony Goodman, Patient Advocate, Men's Health Network http://www.PCaAwareness.com http://www.ProstateHealthGuide.com http://www.ProstateCancerAwarenessMonth.com
Просмотров: 190 MHNMedia
Presentation by Prof. Péter Nyirády MD
Просмотров: 81 Europa Uomo
Jochen Walz, MD, from the Paoli-Calmettes Institute, Marseille, France, discusses the limitations of magnetic resonance imaging (MRI) in prostate cancer diagnosis at the European Association of Urology (EAU) conference 2017 in London, UK. He explains that MRI can be used as a triage test in patients with suspicion of prostate cancer who have not yet had a diagnostic workup for prostate cancer. Some studies have described that if an MRI is negative in this case, there is no need to worry about the presence of significant cancer, while others have observed that significant cancer can be missed when using this approach. A further very important limitation of MRI is related to the quality of this sophisticated technique. Current initiatives to overcome this limitation include the development of a certification process together with the European Society of Urogenital Radiology to establish standards for centers which carry out MRI-based diagnosis for prostate cancer.
Просмотров: 146 VJOncology
Prof. Per-Anders Abrahamsson sits down with The Group Room at EMCC 2011. He discusses the highlights in prostate cancer at the 2011 European Multidisciplinary Cancer Conference in Stockholm.
Просмотров: 309 Vital Options International
Axel Merseburger, from the Schleswig-Holstein University Hospital, Lübeck, Germany, speaks about highlights from the session on advanced prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He says that there was a lot of discussion about advanced prostate cancer, such as what to do with lymph node recurrence after prostatectomy if cancer is found in a small number of lymph nodes in the pelvis after a period of remission. A subsequent presentation covered the complications of this procedure. The session also covered systemic therapy in metastatic castration-resistant prostate cancer, and Prof. Merseburger highlights a study of Radium-223 in combination with androgen receptor (AR)-targeted therapy. Prof. Merseburger describes work which investigated how often imaging should be carried out in prostate cancer.
Просмотров: 330 VJOncology
Hendrik Van Poppel, MD, PhD, from KU Leuven, Leuven, Belgium, discusses localized approaches in the treatment of prostate cancer at the European Association of Urology (EAU) conference in 2017 in London, UK. He explains that the current landscape is primarily hypofractionated radiation therapy, and prostatectomy, which is more recently being carried out by robotic surgery. Photodynamic therapy (PDT) is a novel treatment that has shown to be effective. PDT is promising because it does not carry the same risks as more conventional treatments, and there is potential for it to be used in patients with low risk prostate cancer under active surveillance who ask for localized treatment.
Просмотров: 39 VJOncology
# 1 Management and treatment of advanced prostate cancer; # 2 Stem cell for reconstruction of the lower urinary tract; # 3 Tadalafil once daily treatment; # 4 Pelvic floor exercises can be effective in treating premature ejaculation.
Просмотров: 5360 divulgazione
Christian Stief, MD, from Ludwig-Maximilians-University, Munich, Germany discusses results from the ProtecT trial in prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. This Phase III prospective randomized clinical trial evaluated the efficacy of different treatment modalities in low and intermediate risk prostate cancer. He outlines the data presented at EAU 2017, which focused on histological features of tissue from patients in the ProtecT trial. Discriminating between patients that progressed and those that did not, pathophysiology was retrospectively assessed in biopsy tissue, as well as the entire prostate if surgery was carried out. He explains that the classical D’Amico classification pattern is not sufficient to determine if a patient will progress, but that more features are needed. According to Prof. Stief, these pathohistological features should be assessed before a patient is advised what strategies can be taken with their specific prostate cancer in their specific situation.
Просмотров: 60 VJOncology
Prof. Michael Marberger sits down with The Group Room at EMCC 2011. He discusses the highlights in advanced prostate cancer therapy treatments at the 2011 European Multidisciplinary Cancer Conference in Stockholm.
Просмотров: 1539 Vital Options International
Hendrik Van Poppel, MD, PhD, from KU Leuven, Leuven, Belgium, discusses the potential impact of multi-parametric MRI (mpMRI) in patients with prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. Imaging of prostate cancer typically involves the use of transrectal ultrasounds, however, recently, mpMRI has come to the forefront. mpMRI is currently only used in the diagnosis of patients who have had a negative biopsy. Prof. Van Poppel explains that there is potential for using mpMRI to monitor patients with low-risk prostate cancer, where active treatment, such as radiotherapy or prostatectomy, is not proposed. He states that this is an important development in prostate cancer imaging that has been highlighted at this year’s congress.
Просмотров: 24 VJOncology
Bertrand Tombal, MD, PhD, Catholic University of Leuven, Leuven, Belgium, discusses survivorship at the European Association of Urology (EAU) conference 2017 in London, UK. Survivorship is often confused with overall survival, however it is instead the quality of life of survivors. The prognosis for high risk localized prostate cancer is very good, with approximately 90 to 95% surviving for 10 years or more. Despite being in a durable remission, there may be physical, emotional, and socio-economic consequences from treatment. Therefore there needs to be a switch in attention between those who survive, and how they can be helped, compared to the comparatively small minority of individuals that die.
Просмотров: 48 VJOncology
Kurt Miller, MD, PhD, from Charité University Hospital, Berlin, Germany, discusses the role of Radium-223 in prostate cancer at the European Association of Urology (EAU) conference in 2017 in London, UK. Radium-223 has been used in the treatment of metastatic castration resistant prostate cancer in the past couple of years. In a recent iEAP, Radium-223 combined with abiraterone or enzalutamide (NCT02034552) was shown to have a significant survival advantage. There is currently a phase 3 study comparing the combination of abiraterone with Radium-223 to abiraterone alone (NCT02043678). The results of the study have not yet been released, but if they are positive, this would also have an impact on daily clinical practice.
Просмотров: 54 VJOncology
Mark Emberton, MD, FRCS Urol, from University College London Hospitals NHS Foundation Trust, London, UK, discusses the potential of intraprostatic PRX302 injection for prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights the advantages of imaging technologies to visualize the tumor, and speaks about how this allows localized treatment to be carried out and what this means for the patient. Prof. Emberton describes different approaches for targeting the tumor, including energy sources and pharmaceutical approaches, and outlines how the effects of the bacterial toxin PRX302 can be limited to the prostate. He speaks about safety results from a Phase I trial of PRX302 (NCT00379561), and the ongoing Phase IIa trial (NCT02499848).
Просмотров: 532 VJOncology
Amsterdam September 29, 2013 - European Cancer Congress 2013 (ECCO-ESMO-ESTRO) Pressbriefing Professor Mathieu Boniol: PSA prostate cancer screening: does it do more harm than good? More info @ http://web.oncoletter.ch
Просмотров: 265 oncoletter
Stacey Kenfield, DSc gives an overview of her talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. Dr Kenfield talks about how lifestyle changes, such as physical activity and diet, can reduce the risk of progression of prostate cancer.
Просмотров: 309 European Medical Group
Dr. Laurence Klotz and Dr. Mack Roach, III presented a debate on “Comparative Effectiveness of Surgery and Radiation: Surgery Is Better” versus “Radiotherapy Yields Better Oncologic Outcomes than Radical Prostatectomy for Clinically Localized Prostate Cancer” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016. STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME). The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal. Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
Просмотров: 2749 Grand Rounds in Urology
This course will address contemporary concepts and controversies about one of the most studied minimally invasive treatment options of prostate cancer – cryoablation, such as: - Indications and contraindications, patients’ selection, technical issues - Clinical effectiveness in different groups of patients, definitions of success and failure, quality of life evaluation - Focal cryoablation Objectives are - To refresh your knowledge about cryoablation of the prostate and (probably) destroy skepticism on prostate cancer treatment options other than radical prostatectomy
Просмотров: 373 European Association of Urology
Micropos exhibited the RayPilot® System for real-time tumor localization at the 2nd European Conference on Innovative Radiation Technologies (EC-IRT): "What about hypo-fractionation: slight, moderate, extreme or not at all"? in the beautiful city of Berlin. The RayPIlot® System has been in clinical use in Europe since 2010 on prostate cancer patients. The goal with RayPilot® is to enable focused treatment on the tumor and less harm on the healthy surrounding tissue. Real-time localization is also needed in order to treat with hypo-fractionated protocols
Просмотров: 255 Micropos Medical
Gerald Mickisch, MD, from the Bremen Center of Operative Urology, Bremen, Germany, discusses how sequential therapy can be used in the treatment of castration-resistant prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. Prof. Mickisch explains the efficacy of sequential therapy, and speaks about the order in which treatments are typically given to improve overall survival (OS).
Просмотров: 39 VJOncology
Bertrand Tombal, MD, PhD, Catholic University of Leuven, Leuven, Belgium, discusses the ARASENS trial for prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights the three pillars of prostate cancer treatment: androgen deprivation therapy, androgen receptor suppression, and chemotherapy. Prof. Tombal introduces the hypothesis that combining these treatments will improve overall survival (OS), on which the Phase III ARASENS trial (NCT02799602) is based, and outlines the design of this study.
Просмотров: 69 VJOncology
Kurt Miller, MD, Phd, from Charité University Hospital, Berlin, Germany, discusses the combination of chemotherapy and hormone therapy at the European Association of Urology (EAU) conference in 2017 in London, UK. Treatment for hormone-sensitive metastatic prostate cancer used to involve androgen deprivation therapy, however a combination of chemotherapy and hormone therapy is now being used based on three recent studies; the GETUG study (NCT00104715) from France, the CHAARTED study (NCT00309985) from the US, and the STAMPEDE study (NCT00268476) from the UK. These studies all show that this combination confers a significant survival advantage. The STAMPEDE trial found a survival advantage of 22 months, the longest for any study on prostate cancer so far. This has been integrated into the EAU guidelines, and approximately 60-70% of patients now receive this treatment. There are still questions on whether every patient will benefit from this. The CHAARTED study has been re-evaluated, and it was determined that low volume disease patients do not have a survival advantage. The difference in number and location of metastases between low volume and high volume disease does not currently have a strict definition. He states that this is the only recent development in terms of treating metastatic disease.
Просмотров: 105 VJOncology
A speech given by John Neate, Chief Executive of The Prostate Cancer Charity (UK), in which he addresses the media response to their awareness campaign and the current financial cutbacks on treatment imposed by the NHS. (Part two of two)
Просмотров: 528 Prostate Cancer UK
Susanne Osanto, MD, PhD, from the Leiden University Medical Center, Leiden, Netherlands, discusses the clinical implications of circulating tumor cell (CTC) analysis in prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. She argues that for patients with localized prostate cancer, there is currently no evidence that circulating tumor cells can be used in a clinical setting to monitor disease or treatment outcomes. In contrast, in patients with a higher tumor load, such as those with castration-resistant prostate cancer (CRPC) who need to undergo systemic treatment or in whom we know that treatment resistance has developed and patients need to be selected for targeted treatments, there is more evidence that CTCs can be used. However, she highlights that more data and prospective trials are needed to verify these findings. She concludes that the future is bright; while the clinical utility of CTCs is better proven in castration-resistant prostate cancer with high tumor burden, using CTCs, cell-free DNA or measurement of exosomes will be very important for selecting prostate cancer treatments in future.
Просмотров: 30 VJOncology
According to research presented by Professor Mathieu Boniol, at the 2013 European Cancer Congress (ECC 2013) men experience more harm than good from routine PSA screening. Prostate cancer screening using the prostate-specific antigen (PSA) test is widely used in France despite a lack of evidence showing that it reduces cancer deaths. Prof Boniol, Research Director at the International Prevention Research Institute (iPRI) and Professor at the Strathclyde Institute for Global Public Health at iPRI, Lyon, France, will tell the congress that the total harm men experience in terms of impotence and incontinence, and the side-effects from prostate cancer treatments, severely affects their quality of life, and should further discourage the use of PSA testing for prostate cancer screening.
Просмотров: 408 ecancer
Hendrik Van Poppel, MD, PhD, from KU Leuven, Leuven, Belgium, discusses the advantages of using population based screening to prevent prostate cancer mortality at the European Association of Urology (EAU) conference 2017, in London, UK. The ERSPC study provided evidence that population based screening of PSA reduces prostate cancer mortality, conflicting with both Swedish and American data. The problem with population based screening is overtreatment, resulting from over diagnosis, which can be overcome by using MRI and biomarkers. He explains that over the past few years, the EAU have been submitting proposals to the European Parliament and the European Commission in order to create guidelines that lead to more effective screening to prevent over diagnosis.
Просмотров: 4 VJOncology
Rong Na, MD, from the Huashan Hospital, Fudan University, Shanghai, China discusses germline mutations in prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He introduces a study whose aim was to evaluate the association between germline mutations in DNA repair genes and the risk of prostate cancer, which evaluated the rate of carriers in lethal and indolent prostate cancer patients, as well as survival time. Dr Rong Na also discusses the next steps in this study.
Просмотров: 12 VJOncology
Jochen Walz, MD, from the Paoli-Calmettes Institute, Marseille, France, discusses the advantages of using imaging information for prostate cancer diagnosis and management at the European Association of Urology (EAU) conference 2017 in London, UK. Dr Walz explains that prostate cancer, according to EAU guidelines, is currently diagnosed by randomized biopsy without using imaging information to target the tumor. Several technologies are available to promote the use of imaging information in prostate cancer diagnosis. Reliable imaging will allow decisions to be made on whether a cancer needs to be treated or followed by active surveillance. He concludes that the use of imaging can result in effective treatment of a cancer which may be lethal or affect quality of life.
Просмотров: 24 VJOncology
2002 (Saturday, Sept 28th) Conference on Aging re: State of the Prostate at the Adams Mark (AKA Crowne Plaza & Wyndham) Hotel along the famed RiverWalk in downtown San Antonio, Texas, USA. PM panel on the Quality of Life in Older Men with Prostate Cancer with a quartet of speeches specific to 1. "Quality of Life Definitions" by Carol M. Moinpour, PhD | Behavioral Scientist, SouthWest Oncology Group (SWOG), Fred Hutchinson Cancer Research Center, Seattle, WA. 2. "Sexual Dysfunction" by Leroy Jones, MD | Professor & Urologist, Department of Medicine, University of Texas Health Science Center (UTHSCSA) in San Antonio, TX. 3. "Urinary Dysfunction" by Betsy Osmeis, RN, BSN | Director, South Texas Pelvis Floor & Bladder Center, Department of Surgery, UTHSCSA, TX. 4. "Bone Loss & Osteoporosis" by Jan Bruder, MD | Professor & Clinician, Division of Endocrinology, UTHSCSA, TX. Moderator: Charles Mouton, MD | Professor, Family & Community Medicine, UTHSCSA, San Antonio (AKA The Alamo City), Bexar County, Texas, USA. Quality geri-ed by docs for docs (and other proactive caregivers). Honor this esteemed presenter by redistributing these teaching MedEdVids via Social Media (e.g., FaceBook, Linked-In, Twitter, etc.) Made for and by the South Texas Geriatric Education Center (STGEC) | One of four dozen competitive grant funded GECs across US. With one GEC MedEdVid click you can secure more geriatric education ranging from dementia & pharmacy to caregiving & diabetes. Some information may become dated with the shuffling gait of time so it behooves you to consult your own local health care teams. Funded in part by federal (HHS/HRSA) grants during the helpful Obama Administration. See related videos on this same YT channel. It's requested that viewers like you consider LIKING & SHARING this gratis/gratifying video before SUBSCRIBING to GEC MedEdVids. (The views, opinions, or conclusions expressed in these continuing education enduring materials are not given nor endorsed by any city, county, state or federal institution or authority.)
Просмотров: 214 GEC MedEdVids
The new EAU Update on Prostate Cancer (PCa17) is a unique and fully interactive, expert-led educational meeting focused on prostate cancer (PCa) management. More information about registration and the scientific programme: http://pca17.uroweb.org/ With case discussions and 16 breakout sessions, participants will interact with some of the best international experts on PCa management. Covering topics ranging from localised tumours to metastatic disease, key opinion leaders will lead the critical assessment of best practices and new treatment options. A complete update, the two-day meeting in Vienna is interactive, practical and results-oriented. Watch the video for a quick preview!
Просмотров: 437 European Association of Urology
Karen Kennedy, PhD, Director of the National Cancer Research Institute (NCRI), gives an overview of the 2015 NCRI Cancer Conference. The conference covers the whole range of cancer research from prevention and early diagnosis through basic science, translational science, clinical research, survivorship and palliative care research. Karen Kennedy also discusses recent NCRI initiatives on pathology research, and long-standing initiatives on radiotherapy and survivorship.
Просмотров: 96 European Medical Group
Mark Emberton, MD, FRCS Urol, from University College London Hospitals NHS Foundation Trust, London, UK discusses the value of videos to communicate science at the European Association of Urology (EAU) conference 2017 in London, UK.
Просмотров: 12 VJOncology
Dr. Axel Merseburger presented “Predicting Survival of Men with Prostate Cancer after RP” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016. STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME). The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal. Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
Просмотров: 69 Grand Rounds in Urology
Maurizio Brausi, MD, from the AUSL Modena, B. Ramazzini Hospital, Modena, Italy, discusses the use of robotic surgery for urological cancers at the European Association of Urology (EAU) conference 2017 in London, UK. He describes the joint session with ERUS, the EAU Robotics section, where kidney, bladder and prostate cancer surgery were debated, comparing open surgery with robotic surgery. Prof. Brausi explains that results are good, both with open and robotic surgery. Taking prostate cancer as an example, oncological results do not differ significantly between the different surgical approaches, however robotics is superior when assessing quality of life, erectile dysfunction or continence. Prof. Brausi adds that robotics also gives better results in terms of blood loss and post-operative recovery, with patients able to return home after one day in most cases. However, he points out that costs must also be considered, and that robotic surgery is currently very expensive. Ways to reduce costs include the establishment of platforms at institutions where many different surgeons can work together, including general surgeons, urologists and transplant surgeons, as well as forming high-volume specialized centers for robotic surgery. For muscle invasive bladder cancer, the proportion of robotic surgery is increasing from 4% to 12%. Open surgery is still the standard, but the use of robotics can result in fewer complications, less blood loss and enhanced recovery, with oncological results similar between open and robotic surgery. Prof. Brausi argues that while improvements must still be made, robotics is here to stay. The main consideration is cost. A radical cystectomy requires the patient to stay in the operating room for at least 4 hours with open surgery, and around 6 or 7 hours with robotic surgery. Prof. Brausi points out that being in the surgery position for 7 hours can result in some problems for the patient, and that the length of surgery must be reduced, both from a patient perspective and a cost perspective, as every hour in the operating room costs over €1000.
Просмотров: 89 VJOncology